Skip to Content

Posts tagged with "Academia (vs. Industry)"

  • Academia (vs. Industry)

    The NIH in the Clinic

    OK, I couldn’t resist. Let me reiterate that I completely admire the NIH’s commitment to basic research; it’s one of the real drivers of science in this country. But they’re not a huge factor in clinical trials. Academia does more basic research than pharma; pharma does more clinical work than academia. Here are some statist… Read More
  • Academia (vs. Industry)

    One More On Basic Research and the Clinic

    OK, one more on this topic before moving on to other things for a while. The Bedside Matters medblog has a better roundup of the reactions to my post than I could have done myself. And “Encephalon” there also has one of the longer replies I’ve seen to my initial post, worth reading in full. Read More
  • Academia (vs. Industry)

    A Real-World Can O’ Worms

    Here’s another example of academica and industry, and how it can be hard to divide out the credit. There’s a family of nuclear receptor proteins known as PPARs, a very important (and difficult to unravel) group. The whole field got started years ago, when it was noticed that some compounds had a very particular effect… Read More
  • Academia (vs. Industry)

    How Much Basic Research?

    My long cri de couer last week continues to bring in a number of comments, which I appreciate. Matthew Holt of the Health Care Blog asks: How much money does the NIH spend on basic research and how much does the pharma business spend on it (and you can include development if you like)? I… Read More
  • Academia (vs. Industry)

    How It Really Works

    So is this the attitude we’re up against? Here’s a thread on Slashdot on the clinical trial disclosure issue – titled, I note in light of yesterday’s post, “Medical Journals Fight Burying of Inconvenient Research”. My favorite verb again! The comments range from the insightful to the insipid (for another good rea… Read More
  • Academia (vs. Industry)

    Will the Uncommon Work for the Common Good?

    Yochai Benkler of the Yale Law School has an interesting policy article in a recent issue of Science. It’s on the “Problems of Patents”, and he’s wondering about the application of open-source methods to scientific research. He has two proposals, one of which I’ll talk about today. In some sort of ideal world (which fo… Read More
  • Academia (vs. Industry)

    Industry vs. Academia: The Mental Aspect

    It’s been a while since I returned to this topic. Many differences remain for me to talk about, but I though that it was time to address the biggest one, which is psychological. Some of you probably thought that the biggest difference was money. Can’t ignore that one – it probably contributes to some of… Read More
  • Academia (vs. Industry)

    Stuart Schreiber on Stuart Schreiber

    The April issue of Drug Discovery Today has an intriguing interview (PDF file) with Stuart Schreiber of Harvard. Schreiber is an only partially human presence in the field, as a listing of his academic appointments will make clear: chairman, with an endowed professorship, of the Department of Chemistry at Harvard, investigator at the Howard Hughes… Read More
  • Academia (vs. Industry)

    Differences Between Academia and Industry, Pt. 2

    One of the main things I noticed when I joined the pharmaceutical industry (other than the way my black robe itched and the way the rooster blood stained my shoes, of course) was how quickly one moved from project to project. That’s in contrast to most chemistry grad-school experiences, where you end up on your… Read More
  • Academia (vs. Industry)

    Differences Between Industry and Academia, Pt. 1

    A reader’s e-mail got me thinking about this topic. It’s worth a number of posts, as you’d guess, since there are many substantial differences. Some are merely of degree (funding!), while others are of kind. But the funding makes for larger changes than you’d think, so I’ll get that one out of the way first. Read More
...141516